NCT04154774View on ClinicalTrials.gov

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 7, 2019

Primary Completion Date

February 10, 2025

Study Completion Date

February 10, 2025

Conditions

Hepatic Impairment

Interventions

DRUG

Apalutamide

Apalutamide will be administered orally.

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33033

Homestead Associates in Research Inc, Homestead

33603

Genesis Clinical Research, Tampa

37920

VGR & NOCCR - Knoxville, Knoxville

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT04154774 - A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function | Biotech Hunter | Biotech Hunter